摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-<2-Isopropylmercapto-aethyl>-morpholin | 90726-70-8

中文名称
——
中文别名
——
英文名称
4-<2-Isopropylmercapto-aethyl>-morpholin
英文别名
4-(2-isopropylsulfanyl-ethyl)-morpholine;4-(2-Propan-2-ylsulfanylethyl)morpholine
4-<2-Isopropylmercapto-aethyl>-morpholin化学式
CAS
90726-70-8
化学式
C9H19NOS
mdl
——
分子量
189.322
InChiKey
JMZULFROLJHPDP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    12
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    37.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Oligonucleotide compositions and methods thereof
    申请人:WAVE LIFE SCIENCES LTD.
    公开号:US10450568B2
    公开(公告)日:2019-10-22
    Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
    除其他外,本公开涉及设计的寡核苷酸、组合物及其方法。在一些实施方案中,所提供的寡核苷酸组合物能改变转录本的剪接。在一些实施方案中,所提供的寡核苷酸组合物具有低毒性。在一些实施方案中,所提供的寡核苷酸组合物提供了改进的蛋白质结合概况。在一些实施方案中,所提供的寡核苷酸组合物具有更好的传递性。在一些实施方案中,所提供的寡核苷酸组合物改善了吸收。在一些实施方案中,本公开提供了使用所提供的寡核苷酸组合物治疗疾病的方法。
  • CHIRAL DESIGN
    申请人:WAVE LIFE SCIENCES LTD.
    公开号:US20170037399A1
    公开(公告)日:2017-02-09
    The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
  • OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
    申请人:Vargeese Chandra
    公开号:US20180216108A1
    公开(公告)日:2018-08-02
    Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
  • [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
    申请人:WAVE LIFE SCIENCES LTD
    公开号:WO2017192664A1
    公开(公告)日:2017-11-09
    Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
  • Tsatsas,G. et al., Bulletin de la Societe Chimique de France, 1963, p. 2160 - 2162
    作者:Tsatsas,G. et al.
    DOI:——
    日期:——
查看更多

同类化合物

(4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (2-肟基-氰基乙酸乙酯)-N,N-二甲基-吗啉基脲六氟磷酸酯 鲸蜡基乙基吗啉氮鎓乙基硫酸盐 马啉乙磺酸钾 预分散OTOS-80 顺式4-(氮杂环丁烷-3-基)-2,2-二甲基吗啉 顺式-N-亚硝基-2,6-二甲基吗啉 顺式-3,5-二甲基吗啉 顺-2,6-二甲基-4-(4-硝基苯基)吗啉 非屈酯 雷奈佐利二聚体 阿瑞杂质9 阿瑞吡坦磷的二卞酯 阿瑞吡坦杂质 阿瑞吡坦杂质 阿瑞吡坦 阿瑞吡坦 阿瑞匹坦非对映异构体2R3R1R 阿瑞匹坦杂质A异构体 阿瑞匹坦杂质54 阿瑞匹坦-M3代谢物 钾[2 - (吗啉- 4 -基)乙氧基]甲基三氟硼酸 邻苯二甲酸单吗啉 调节安 试剂2-(4-Morpholino)ethyl2-bromoisobutyrate 茂硫磷 苯甲腈,2-(4-吗啉基)-5-[1,4,5,6-四氢-4-(羟甲基)-6-羰基-3-哒嗪基]- 苯甲曲秦 苯甲吗啉酮 苯基2-(2-苯基吗啉-4-基)乙基碳酸酯盐酸盐 苯二甲吗啉一氢酒石酸盐 苯二甲吗啉 苯乙酮 O-(吗啉基羰基甲基)肟 芬美曲秦 芬布酯盐酸盐 芬布酯 脾脏酪氨酸激酶(SYK)抑制剂 脱氯利伐沙班 脱氟雷奈佐利 羟基1-(3-氯苯基)-2-[(1,1-二甲基乙基)氨基]-1-丙酮盐酸盐 福沙匹坦苄酯 福沙匹坦杂质26 福曲他明 碘化N-甲基丙基吗啉 碘化N-甲基,乙基吗啉 硝酸吗啉 盐酸吗啡啉-D8 甲基吗啉-2-羧酸甲酯2,2,2-三氟乙酸盐 甲基N-[3-(乙酰基氨基)-4-[(2-氰基-4,6-二硝基苯基)偶氮]苯基]-N-乙基-&#x3B2-丙氨酸酸酯 甲基4-吗啉二硫代甲酸酯